mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic

por Van Lint, Sandra, Heirman, Carlo, Thielemans, Kris, Breckpot, Karine
Publicado 2013

Dendritic Cell-Based Immunotherapy in Lung Cancer

por Stevens, Dieter, Ingels, Joline, Van Lint, Sandra, Vandekerckhove, Bart, Vermaelen, Karim
Publicado 2021

mRNA in cancer immunotherapy: beyond a source of antigen

por Van Hoecke, Lien, Verbeke, Rein, Dewitte, Heleen, Lentacker, Ine, Vermaelen, Karim, Breckpot, Karine, Van Lint, Sandra
Publicado 2021

The Opposing Effect of Type I IFN on the T Cell Response by Non-modified mRNA-Lipoplex Vaccines Is Determined by the Route of Administration

por Van Hoecke, Lien, Roose, Kenny, Ballegeer, Marlies, Zhong, Zifu, Sanders, Niek N., De Koker, Stefaan, Saelens, Xavier, Van Lint, Sandra
Publicado 2020

Treatment with mRNA coding for the necroptosis mediator MLKL induces antitumor immunity directed against neo-epitopes

por Van Hoecke, Lien, Van Lint, Sandra, Roose, Kenny, Van Parys, Alexander, Vandenabeele, Peter, Grooten, Johan, Tavernier, Jan, De Koker, Stefaan, Saelens, Xavier
Publicado 2018

Targeting the tumor microenvironment to enhance antitumor immune responses

por Van der Jeught, Kevin, Bialkowski, Lukasz, Daszkiewicz, Lidia, Broos, Katrijn, Goyvaerts, Cleo, Renmans, Dries, Van Lint, Sandra, Heirman, Carlo, Thielemans, Kris, Breckpot, Karine
Publicado 2014

Targeting IFN activity to both B cells and plasmacytoid dendritic cells induces a robust tolerogenic response and protection against EAE

por Cauwels, Anje, Van Lint, Sandra, Rogge, Elke, Verhee, Annick, Van Den Eeckhout, Bram, Pang, Shengru, Prinz, Marco, Kley, Niko, Uzé, Gilles, Tavernier, Jan
Publicado 2021

Specific targeting of IL-1β activity to CD8(+) T cells allows for safe use as a vaccine adjuvant

por Van Den Eeckhout, Bram, Van Hoecke, Lien, Burg, Elianne, Van Lint, Sandra, Peelman, Frank, Kley, Niko, Uzé, Gilles, Saelens, Xavier, Tavernier, Jan, Gerlo, Sarah
Publicado 2020

Selective IL-1 activity on CD8(+) T cells empowers antitumor immunity and synergizes with neovasculature-targeted TNF for full tumor eradication

por Van Den Eeckhout, Bram, Huyghe, Leander, Van Lint, Sandra, Burg, Elianne, Plaisance, Stéphane, Peelman, Frank, Cauwels, Anje, Uzé, Gilles, Kley, Niko, Gerlo, Sarah, Tavernier, Jan
Publicado 2021

Design of an Optimized Wilms' Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo

por Benteyn, Daphné, Anguille, Sébastien, Van Lint, Sandra, Heirman, Carlo, Van Nuffel, An MT, Corthals, Jurgen, Ochsenreither, Sebastian, Waelput, Wim, Van Beneden, Katrien, Breckpot, Karine, Van Tendeloo, Viggo, Thielemans, Kris, Bonehill, Aude
Publicado 2013

Safe eradication of large established tumors using neovasculature‐targeted tumor necrosis factor‐based therapies

por Huyghe, Leander, Van Parys, Alexander, Cauwels, Anje, Van Lint, Sandra, De Munter, Stijn, Bultinck, Jennyfer, Zabeau, Lennart, Hostens, Jeroen, Goethals, An, Vanderroost, Nele, Verhee, Annick, Uzé, Gilles, Kley, Niko, Peelman, Frank, Vandekerckhove, Bart, Brouckaert, Peter, Tavernier, Jan
Publicado 2020

A bispecific Clec9A-PD-L1 targeted type I interferon profoundly reshapes the tumor microenvironment towards an antitumor state

por Van Lint, Sandra, Van Parys, Alexander, Van Den Eeckhout, Bram, Vandamme, Niels, Plaisance, Stephane, Verhee, Annick, Catteeuw, Dominiek, Rogge, Elke, De Geest, Jennifer, Vanderroost, Nele, Roels, Jana, Saeys, Yvan, Uzé, Gilles, Kley, Niko, Cauwels, Anje, Tavernier, Jan
Publicado 2023